Dr. Melvin Chua
MBBS, FRCR (Clinical Oncology), PhD, FAMS, FASCO
Head and Senior Consultant Radiation Oncologist
corporate_fareNational Cancer Centre Singapore
Melvin Chua
MBBS, FRCR (Clinical Oncology), PhD, FAMS, FASCO
Dr. Melvin Chua is Head and Senior Consultant in the Department of Head and Neck and Thoracic Cancers at the National Cancer Centre Singapore (NCCS), and Associate Professor at Duke-NUS Medical School. He is also Principal Investigator of the Precision Radiotherapeutics and Oncology Programme and Director of the Data and Computational Science Hub/Core at NCCS.
With more than two decades since his MBBS in 2002, Dr. Chua has built a widely cited body of work in radiation oncology, nasopharyngeal carcinoma, prostate cancer, and genitourinary malignancies. NCCS records over 200 peer-reviewed publications attributed to him, with an H-index of 44 and more than 11,000 citations, including contributions to the New England Journal of Medicine, The Lancet, Nature, Journal of Clinical Oncology, and JAMA Oncology. He served as Chair of the Nasopharyngeal Carcinoma Expert Panel for the AJCC/UICC TNM Staging 9th edition and as Lead Investigator of the Singapore Nasopharyngeal Carcinoma Large Collaborative Grant Programme. His clinical and translational work spans biomarker-directed radiotherapy, radiotherapy resistance, computational genomics, and precision radiation oncology.
CancerFax can coordinate medical-report review, second opinion submissions, and consultation support for international patients seeking guidance from Dr. Chua at NCCS Singapore.
Why Consider Dr. Melvin Chua?
Dr. Chua combines senior clinical leadership at Singapore's leading specialist cancer centre with one of the most extensive radiation oncology research records in the Asia-Pacific region.
Areas of Specialisation
Precision radiation oncology for head and neck, genitourinary, and thoracic cancers
Dr. Chua's clinical practice is focused on radiation oncology for head and neck cancers including nasopharyngeal carcinoma, as well as prostate cancer, bladder cancer, and other genitourinary malignancies. His approach integrates biomarker-directed treatment planning, phase II–III clinical trial involvement, and computational oncology to support individualised radiotherapy.
Head & Neck Radiation Oncology
Specialist radiotherapy for nasopharyngeal carcinoma, laryngeal cancer, oral cancer, salivary gland cancer, and other head and neck malignancies.
- arrow_rightDefinitive and adjuvant radiotherapy planning for NPC
- arrow_rightBiomarker-directed treatment protocol selection
- arrow_rightPhase II–III clinical trial-based approaches for locoregionally advanced disease
- arrow_rightRisk-adaptive radiotherapy informed by TNM 9th edition staging criteria
- arrow_rightRadiation planning for laryngeal, oral, and salivary gland cancers
- arrow_rightMultidisciplinary tumour board integration for treatment sequencing
- arrow_rightOrgan-preservation radiotherapy protocols where clinically appropriate
Prostate and Genitourinary Radiation Oncology
Evidence-based radiotherapy for prostate cancer, bladder cancer, and other genitourinary malignancies, incorporating genomic and biomarker-directed risk stratification.
- arrow_rightExternal beam radiotherapy for localised and locally advanced prostate cancer
- arrow_rightGenomic and biomarker-directed risk stratification for treatment planning
- arrow_rightClinical trial-based approaches for selected patients
- arrow_rightRadiation management for bladder cancer
- arrow_rightMultidisciplinary coordination with urologic oncology
- arrow_rightPrecision radiotherapy planning using computational and imaging-based approaches
Procedures & Radiation Oncology Services
Clinical radiation oncology services at the National Cancer Centre Singapore
Dr. Chua provides specialist radiation oncology services for head and neck cancers, genitourinary malignancies, and thoracic cancers, with an emphasis on precision radiotherapy, biomarker-directed planning, and clinical trial access.
Head & Neck Radiation Oncology
MultidisciplinarySpecialist radiotherapy for nasopharyngeal carcinoma, laryngeal cancer, oral cancer, and salivary gland cancer, delivered within a multidisciplinary framework.
Prostate & Genitourinary Radiation Oncology
Complex DiseaseRadiation oncology for prostate cancer, bladder cancer, and other genitourinary malignancies, incorporating biomarker and genomic risk stratification.
Precision Radiotherapy and Translational Research
MultidisciplinaryBiomarker-directed and computationally informed precision radiation oncology, supported by an active translational research programme.
Second Opinion Consultation
Second OpinionIndependent specialist review of radiation oncology treatment plans, pathology, and staging for head and neck, genitourinary, and thoracic cancers.
Research & Publications
200+ peer-reviewed papers and international guideline leadership in radiation oncology
Dr. Chua is one of the most published radiation oncologists in the Asia-Pacific region, with a research portfolio spanning nasopharyngeal carcinoma, prostate cancer, radiotherapy resistance, computational genomics, biomarker discovery, and oncology data science.
Dr. Chua's ongoing clinical trial leadership at NCCS may provide eligible patients with access to investigational radiation oncology approaches. CancerFax can help assess trial eligibility as part of consultation coordination.
Education & Training
Dr. Chua completed his MBBS in 2002 and subsequently trained in clinical oncology and earned a PhD in Cancer and Radiation Biology at University College London. He holds Fellowship of the Royal College of Radiologists, the Academy of Medicine Singapore, and the American Society of Clinical Oncology.
Clinical Experience
Dr. Chua has built his entire career at the National Cancer Centre Singapore, where he currently serves as Head and Senior Consultant in the Department of Head and Neck and Thoracic Cancers, alongside concurrent academic and research leadership appointments.
Languages & International
Dr. Chua conducts consultations in English, as listed on his NCCS profile.
CancerFax can coordinate professional medical interpreter support for international patients requiring consultations in languages other than English.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Melvin Chua
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Melvin Chua's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Melvin Chua's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Melvin Chua before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Melvin Chua's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Melvin Chua's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Melvin Chua's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Melvin Chua
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Chua at the National Cancer Centre Singapore, subject to hospital availability and case acceptance. NCCS provides appointment pathways, and CancerFax can assist with case preparation, medical summaries, and logistical support.
Dr. Chua specialises in radiation oncology for head and neck cancers — particularly nasopharyngeal carcinoma, laryngeal cancer, oral cancer, and salivary gland cancer — as well as prostate cancer, bladder cancer, and other genitourinary malignancies. His NCCS profile lists bladder cancer, head and neck cancer, larynx cancer, nasopharyngeal cancer, oral cancer, prostate cancer, and salivary gland cancer among the conditions he treats.
Submit your medical reports through CancerFax using the Send Your Reports button. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps with NCCS, subject to availability. We handle case preparation and pre-consultation logistics so you can focus on your care.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, staging documents, treatment history, and relevant test results. Dr. Chua's expertise in radiation oncology for head and neck cancers, nasopharyngeal carcinoma, and prostate cancer makes him particularly well suited for cases where a specialist radiotherapy perspective is required. The final consultation format and availability depend on NCCS scheduling.
Yes. Dr. Chua is an active clinical trial investigator and Principal Investigator of the Precision Radiotherapeutics and Oncology Programme at NCCS. He has co-led randomised controlled trials in nasopharyngeal carcinoma and prostate cancer. CancerFax can help assess whether an eligible patient may be considered for open trials as part of the consultation coordination process.
Dr. Chua has published more than 200 peer-reviewed papers with an H-index of 44 and over 11,000 citations, according to his NCCS profile. He has been recognised as a World's Top 2% Most Cited Scientist in 2023 and 2024, chaired the Nasopharyngeal Carcinoma Expert Panel for AJCC/UICC TNM Staging 9th edition, and contributed to international ASCO-CSCO guidelines. He also serves as Editor-in-Chief of the Annals of Nasopharynx Cancer.
Connect with Melvin Chua Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.